Roche extends offer for Spark until Nov. 25

ZURICH (Reuters) - Roche <ROG.S> said it extended its tender offer for shares of Spark Therapeutics, Inc. <ONCE.O> until Nov. 25 to give the U.S. Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) more time to complete their reviews of the $4.3 billion deal.

The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA, Roche and Spark said in a joint statement on Tuesday.

The UK competition watchdog had launched an inquiry into the pending acquisition earlier this month.

(Reporting by Silke Koltrowitz, editing by Riham Alkousaa)